RCTs have shown evidence that p38 MAPK inhibition resulted in anti-inflammatory effects when used in combination with dexamethasone (synthetic glucocorticoid) on glucocorticoid receptor (GR) target gene expression through a significant reduction of LPS-induced IL-6 secretion associated with asthma in lung cells [147,148]. Here, NR3C1 is linked to asthma.